Roger Leng

2.5k total citations · 1 hit paper
41 papers, 1.9k citations indexed

About

Roger Leng is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Roger Leng has authored 41 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Molecular Biology, 22 papers in Oncology and 8 papers in Cancer Research. Recurrent topics in Roger Leng's work include Cancer-related Molecular Pathways (18 papers), Ubiquitin and proteasome pathways (11 papers) and Antifungal resistance and susceptibility (6 papers). Roger Leng is often cited by papers focused on Cancer-related Molecular Pathways (18 papers), Ubiquitin and proteasome pathways (11 papers) and Antifungal resistance and susceptibility (6 papers). Roger Leng collaborates with scholars based in Canada, United States and United Kingdom. Roger Leng's co-authors include Hong Wu, Samuel Benchimol, Yunping Lin, John M. Parant, Bénédicte Lemmers, Stephen W. Chung, Razqallah Hakem, Weili Ma, Guillermina Lozano and Consolato Sergi and has published in prestigious journals such as Cell, Nucleic Acids Research and Nature Medicine.

In The Last Decade

Roger Leng

41 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation

2003 584 citations Roger Leng, Yunping Lin et al. Cell profile →

Peers

Countries citing papers authored by Roger Leng

Since Specialization

Citations

This map shows the geographic impact of Roger Leng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger Leng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger Leng more than expected).

Fields of papers citing papers by Roger Leng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger Leng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger Leng. The network helps show where Roger Leng may publish in the future.

Co-authorship network of co-authors of Roger Leng

This figure shows the co-authorship network connecting the top 25 collaborators of Roger Leng. A scholar is included among the top collaborators of Roger Leng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger Leng. Roger Leng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Digging Through the Complexities of Immunological Approaches in Emerging Osteosarcoma Therapeutics: A Comprehensive Narrative Review with Updated Clinical Trials 2025 ·Biomedicines ·Consolato Sergi, (unknown), (unknown), (unknown), Shawn T. Beug, Roger Leng, Fan Shen	1
2	Deciphering UBE4B phosphorylation dynamics: a key mechanism in p53 accumulation and cancer cell response to DNA damage 2025 ·Cell Death Discovery ·Yasser Abuetabh, Hong Wu, (unknown), Sujata Persad, (unknown), David D. Eisenstat, Consolato Sergi, Roger Leng	1
3	Targeting p53 for immune modulation: Exploring its functions in tumor immunity and inflammation 2025 ·Cancer Letters ·Hong Wu, (unknown), David D. Eisenstat, Consolato Sergi, Roger Leng	6
4	The role of imprinting genes’ loss of imprints in cancers and their clinical implications 2024 ·Frontiers in Oncology ·(unknown), Qin Si, Guangjie Zhang, Yu Fan, Qinghua Li, Roger Leng, (unknown), Simin Liang, (unknown), (unknown)	3
5	How MicroRNAs Command the Battle against Cancer 2024 ·International Journal of Molecular Sciences ·Hong Wu, (unknown), Consolato Sergi, Roger Leng	10
6	The SWIB/MDM2 motif of UBE4B activates the p53 pathway 2023 ·Molecular Therapy — Nucleic Acids ·Hong Wu, (unknown), Yasser Abuetabh, Consolato Sergi, David D. Eisenstat, Roger Leng	3
7	DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities 2022 ·Experimental & Molecular Medicine ·Yasser Abuetabh, Hong Wu, Chengsen Chai, (unknown), Sujata Persad, Consolato Sergi, Roger Leng	100
8	p63, a key regulator of Ago2, links to the microRNA-144 cluster 2022 ·Cell Death and Disease ·Benfan Wang, Hong Wu, Yasser Abuetabh, (unknown), Sandra T. Davidge, Elsa R. Flores, David D. Eisenstat, Roger Leng	7
9	PathVisio Analysis: An Application Targeting the miRNA Network Associated with the p53 Signaling Pathway in Osteosarcoma 2021 ·Biocell ·(unknown), Vito Rodolico, Fan Shen, Roger Leng, Mingyong Zhang, David D. Eisenstat, Consolato Sergi	2
10	Regulation of the tumor suppressor PTEN in triple-negative breast cancer 2021 ·Cancer Letters ·Chengsen Chai, Hong Wu, Yasser Abuetabh, Consolato Sergi, Roger Leng	48
11	Graphene Oxide Nanoparticles Induce Apoptosis in wild-type and CRISPR/Cas9-IGF/IGFBP3 knocked-out Osteosarcoma Cells 2020 ·Journal of Cancer ·(unknown), Yasser Abuetabh, Ania Wronski, Fan Shen, Sujata Persad, Roger Leng, David D. Eisenstat, Consolato Sergi	35
12	MicroRNA-1301 suppresses tumor cell migration and invasion by targeting the p53/UBE4B pathway in multiple human cancer cells 2017 ·Cancer Letters ·Benfan Wang, Hong Wu, Chengsen Chai, John D. Lewis, Flavia Pichiorri, David D. Eisenstat, Scott L. Pomeroy, Roger Leng	35
13	UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53 2011 ·Nature Medicine ·Hong Wu, Scott L. Pomeroy, Manuel Branco Ferreira, Natalia Teider, (unknown), Keiichi I. Nakayama, Shigetsugu Hatakeyama, Victor A. Tron, (unknown), Leo Spyracopoulos, Roger Leng	96
14	UBE4B, a ubiquitin chain assembly factor, is required for MDM2-mediated p53 polyubiquitination and degradation 2011 ·Cell Cycle ·Hong Wu, Roger Leng	48
15	Developmental Regulation of an Adhesin Gene during Cellular Morphogenesis in the Fungal Pathogen Candida albicans 2007 ·Eukaryotic Cell ·Silvia Argimón, Jill A. Wishart, Roger Leng, (unknown), (unknown), (unknown), Susan M. Nicholls, Andrew W. Knight, Brice Enjalbert, Richard M. Walmsley, Frank C. Odds, Neil A. R. Gow, Alistair J. P. Brown	102
16	Identification of p53-Regulated Genes by the Method of Differential Display 2005 ·Humana Press eBooks ·Yunping Lin, Roger Leng, Samuel Benchimol	1
17	Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation breakdown → 2003 ·Cell ·Roger Leng, Yunping Lin, Weili Ma, Hong Wu, Bénédicte Lemmers, Stephen W. Chung, John M. Parant, Guillermina Lozano, Razqallah Hakem, Samuel Benchimol	584
18	Gene Regulation during Morphogenesis in <i>Candida albicans</i> 2000 ·PubMed ·Alistair J. P. Brown, Caroline J. Barelle, Susan Budge, J.L. Duncan, Stephen Harris, (unknown), Roger Leng, (unknown), Abdul Munir Abdul Murad, Mark Ramsdale, Carolyn Wiltshire, Jill A. Wishart, Neil A. R. Gow	12
19	E2F1 and p53 Are Dispensable, whereas p21Waf1/Cip1 Cooperates with Rb to Restrict Endoreduplication and Apoptosis during Skeletal Myogenesis 2000 ·Developmental Biology ·Zhe Jiang, Ping Liang, Roger Leng, Zhong Guo, Yule Liu, Xudong Liu, (unknown), Armand Keating, David Murray, Paul E. Goss, Eldad Zacksenhaus	24
20	Skipper, an LTR retrotransposon of Dictyostelium 1998 ·Nucleic Acids Research ·Roger Leng	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact